Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2022 | 87 | 1.780 |
Why?
|
| Laryngectomy | 5 | 2020 | 7 | 1.310 |
Why?
|
| Mouth Neoplasms | 2 | 2022 | 63 | 0.910 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 39 | 0.690 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2024 | 164 | 0.660 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2017 | 22 | 0.650 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2018 | 24 | 0.600 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2018 | 7 | 0.590 |
Why?
|
| Image-Guided Biopsy | 2 | 2018 | 20 | 0.590 |
Why?
|
| Larynx, Artificial | 1 | 2017 | 1 | 0.560 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 21 | 0.560 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 26 | 0.560 |
Why?
|
| Prosthesis Design | 1 | 2017 | 87 | 0.550 |
Why?
|
| Cutaneous Fistula | 3 | 2014 | 6 | 0.490 |
Why?
|
| Turbinates | 2 | 2006 | 2 | 0.480 |
Why?
|
| Parathyroidectomy | 3 | 2004 | 5 | 0.470 |
Why?
|
| Hyperparathyroidism | 3 | 2004 | 9 | 0.470 |
Why?
|
| Pharyngeal Diseases | 2 | 2014 | 5 | 0.470 |
Why?
|
| Fascia | 1 | 2014 | 5 | 0.450 |
Why?
|
| Pectoralis Muscles | 1 | 2014 | 13 | 0.450 |
Why?
|
| Skin Transplantation | 1 | 2014 | 15 | 0.440 |
Why?
|
| Surgical Flaps | 1 | 2014 | 23 | 0.440 |
Why?
|
| Humans | 36 | 2024 | 28121 | 0.420 |
Why?
|
| Parathyroid Neoplasms | 2 | 2003 | 4 | 0.410 |
Why?
|
| Middle Aged | 21 | 2024 | 7164 | 0.410 |
Why?
|
| Catheter Ablation | 2 | 2006 | 221 | 0.400 |
Why?
|
| Hypercalcemia | 2 | 2021 | 13 | 0.390 |
Why?
|
| Male | 25 | 2024 | 13487 | 0.380 |
Why?
|
| Tonsillar Neoplasms | 1 | 2010 | 1 | 0.330 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 478 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 21 | 0.330 |
Why?
|
| Female | 23 | 2024 | 15156 | 0.320 |
Why?
|
| Jaw Diseases | 1 | 2009 | 4 | 0.320 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2009 | 4 | 0.320 |
Why?
|
| Osteonecrosis | 1 | 2009 | 8 | 0.310 |
Why?
|
| Diphosphonates | 1 | 2009 | 15 | 0.310 |
Why?
|
| Retrospective Studies | 11 | 2022 | 2557 | 0.300 |
Why?
|
| Osteoma | 1 | 2008 | 3 | 0.300 |
Why?
|
| Mandibular Neoplasms | 1 | 2008 | 5 | 0.300 |
Why?
|
| Mandibular Condyle | 1 | 2008 | 15 | 0.300 |
Why?
|
| Endoscopy | 1 | 2008 | 56 | 0.290 |
Why?
|
| Nasal Obstruction | 2 | 2006 | 7 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2017 | 1249 | 0.270 |
Why?
|
| Hyperostosis | 1 | 2006 | 1 | 0.260 |
Why?
|
| Epistaxis | 2 | 1996 | 7 | 0.250 |
Why?
|
| Aged | 12 | 2018 | 5416 | 0.220 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 5 | 0.220 |
Why?
|
| Adult | 16 | 2024 | 7757 | 0.210 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 1014 | 0.210 |
Why?
|
| Parathyroid Glands | 1 | 2003 | 7 | 0.210 |
Why?
|
| Parathyroid Hormone | 4 | 2021 | 24 | 0.210 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 969 | 0.210 |
Why?
|
| Cysts | 1 | 2003 | 22 | 0.200 |
Why?
|
| Treatment Outcome | 6 | 2021 | 2380 | 0.200 |
Why?
|
| Lymphatic Metastasis | 3 | 2018 | 125 | 0.200 |
Why?
|
| Adenoma | 1 | 2003 | 61 | 0.190 |
Why?
|
| Tobacco Use Cessation | 1 | 2022 | 30 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 73 | 0.190 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2021 | 2 | 0.190 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 10 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 521 | 0.170 |
Why?
|
| HIV Infections | 1 | 2022 | 157 | 0.170 |
Why?
|
| Postoperative Complications | 3 | 2017 | 613 | 0.170 |
Why?
|
| Patient Safety | 1 | 2020 | 38 | 0.170 |
Why?
|
| Time Factors | 3 | 2017 | 1593 | 0.170 |
Why?
|
| Disease Management | 1 | 2020 | 88 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 153 | 0.160 |
Why?
|
| Tracheostomy | 1 | 1999 | 7 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.160 |
Why?
|
| Foreign Bodies | 1 | 1999 | 16 | 0.160 |
Why?
|
| Bronchi | 1 | 1999 | 38 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 477 | 0.150 |
Why?
|
| Malingering | 1 | 1998 | 10 | 0.150 |
Why?
|
| Posture | 1 | 1998 | 39 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 185 | 0.150 |
Why?
|
| Parotid Neoplasms | 1 | 1997 | 4 | 0.140 |
Why?
|
| Lipoma | 1 | 1997 | 11 | 0.140 |
Why?
|
| Voice Quality | 1 | 2017 | 3 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2021 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 2 | 2014 | 8 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2014 | 34 | 0.130 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 372 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 302 | 0.130 |
Why?
|
| Eating | 1 | 2016 | 70 | 0.130 |
Why?
|
| Sickness Impact Profile | 1 | 2016 | 4 | 0.130 |
Why?
|
| Carcinoma | 2 | 2014 | 75 | 0.130 |
Why?
|
| Xerostomia | 1 | 2016 | 9 | 0.130 |
Why?
|
| Cerebral Arteries | 1 | 1996 | 33 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 109 | 0.120 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2016 | 25 | 0.120 |
Why?
|
| Oxymetazoline | 1 | 1995 | 3 | 0.120 |
Why?
|
| Single-Blind Method | 2 | 2006 | 45 | 0.120 |
Why?
|
| Intracranial Aneurysm | 1 | 1996 | 58 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 1996 | 91 | 0.120 |
Why?
|
| Palatal Neoplasms | 1 | 2014 | 2 | 0.120 |
Why?
|
| Palate, Hard | 1 | 2014 | 2 | 0.120 |
Why?
|
| Incidence | 2 | 2014 | 562 | 0.110 |
Why?
|
| Fistula | 1 | 2014 | 17 | 0.110 |
Why?
|
| Pain | 1 | 2016 | 258 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2008 | 411 | 0.100 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2014 | 72 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2006 | 454 | 0.100 |
Why?
|
| Enteral Nutrition | 2 | 2011 | 23 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 491 | 0.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2003 | 70 | 0.100 |
Why?
|
| Biopsy | 2 | 2014 | 207 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 60 | 0.090 |
Why?
|
| Gastroscopy | 1 | 2011 | 7 | 0.090 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2011 | 11 | 0.090 |
Why?
|
| Oklahoma | 1 | 2014 | 1005 | 0.090 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2010 | 5 | 0.090 |
Why?
|
| Round Window, Ear | 1 | 2010 | 10 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2010 | 37 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2010 | 63 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2010 | 67 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 464 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 96 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 29 | 0.080 |
Why?
|
| Cisplatin | 2 | 2008 | 179 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 6 | 0.080 |
Why?
|
| Open Bite | 1 | 2008 | 3 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2010 | 265 | 0.070 |
Why?
|
| Microsurgery | 1 | 2008 | 45 | 0.070 |
Why?
|
| Thyroid Nodule | 1 | 2008 | 8 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 27 | 0.070 |
Why?
|
| Risk Factors | 2 | 2010 | 2084 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 129 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 72 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 100 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 257 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2006 | 59 | 0.060 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2004 | 1 | 0.060 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2004 | 45 | 0.060 |
Why?
|
| Adolescent | 2 | 2024 | 3123 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 134 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 12 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 40 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2003 | 82 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 80 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2003 | 97 | 0.050 |
Why?
|
| Motivation | 1 | 2024 | 213 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2002 | 62 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 12 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2000 | 2 | 0.040 |
Why?
|
| Granuloma, Giant Cell | 1 | 2000 | 3 | 0.040 |
Why?
|
| Maxillary Neoplasms | 1 | 2000 | 2 | 0.040 |
Why?
|
| Bupivacaine | 1 | 2000 | 4 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2002 | 113 | 0.040 |
Why?
|
| Biomarkers | 1 | 2024 | 755 | 0.040 |
Why?
|
| Calcium | 1 | 2021 | 235 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 722 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 13 | 0.040 |
Why?
|
| Patient Care | 1 | 2020 | 13 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2000 | 115 | 0.040 |
Why?
|
| Equipment Failure | 1 | 1999 | 31 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 679 | 0.040 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1999 | 31 | 0.040 |
Why?
|
| Vestibular Diseases | 1 | 1998 | 3 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2018 | 103 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 1999 | 56 | 0.040 |
Why?
|
| Young Adult | 2 | 2018 | 2731 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1998 | 58 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 611 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 1998 | 414 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 46 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 1996 | 38 | 0.030 |
Why?
|
| Osteotomy | 1 | 1996 | 24 | 0.030 |
Why?
|
| Mandible | 1 | 1996 | 43 | 0.030 |
Why?
|
| Cautery | 1 | 1995 | 1 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 1996 | 47 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1995 | 223 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2008 | 475 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 12 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2016 | 94 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 22 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 104 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2014 | 61 | 0.030 |
Why?
|
| Infant | 1 | 1997 | 996 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 462 | 0.030 |
Why?
|
| Child | 1 | 2018 | 2242 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 406 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 28 | 0.020 |
Why?
|
| Perilymph | 1 | 2010 | 2 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2010 | 74 | 0.020 |
Why?
|
| Cachexia | 1 | 2011 | 53 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 825 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 100 | 0.020 |
Why?
|
| Oral Fistula | 1 | 2009 | 2 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 257 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 104 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2008 | 9 | 0.020 |
Why?
|
| Length of Stay | 1 | 2009 | 232 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 5 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2008 | 6 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 40 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 238 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 39 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 190 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 430 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 433 | 0.020 |
Why?
|
| Hydrochlorothiazide | 1 | 2006 | 2 | 0.020 |
Why?
|
| Atenolol | 1 | 2006 | 10 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 432 | 0.020 |
Why?
|
| Albuterol | 1 | 2006 | 4 | 0.020 |
Why?
|
| Creatinine | 1 | 2006 | 57 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2006 | 58 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 330 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 94 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 56 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2004 | 21 | 0.010 |
Why?
|
| Immunoassay | 1 | 2004 | 36 | 0.010 |
Why?
|
| Nurse's Role | 1 | 2002 | 17 | 0.010 |
Why?
|
| Morphine | 1 | 2002 | 29 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2002 | 46 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2002 | 50 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2000 | 6 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2002 | 163 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 10399 | 0.010 |
Why?
|